Laryngeal Allograft Transplantation

Overview

About this study

The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal allograft transplantation in an effort to safely use these procedures as a viable reconstructive option for patients with severe laryngeal or laryngotracheal incompetence.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Ages 18 years and older
  • Male or Female
  • One of the following:
    • Severe laryngeal dysfunction as described above
    • Laryngeal stenosis
    • 5 years or longer s/p definitive management for head and neck cancer
    • Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression
    • Low-grade chondrosarcoma requiring total laryngectomy
  • Ability to obtain informed consent from the patient

Exclusion Criteria:

Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation General medical status

  • Pregnancy
  • Any systemic disease which would alter life expectancy
    • Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer
    • Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion)
    • Obesity (Body Mass Index >29 - 30)(Exceptional cases will be considered on a case by case basis)
    • Cachexia (BMI<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance < 50 ml/min.)
    • Significant hepatic dysfunction
    • Significant kidney damage
    • Unmanageable infections
    • Unable to participate in preoperative exercise training
    • Unable to be weaned to equal or less than 10 mg/day of steroids
    • Untreatable cardiac disease
    • Active neuromuscular disease
    • History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux
    • Patients with active connective tissue diseases (exceptions to be considered in a case by case basis)
    • Patients unable to achieve > 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis)
    • Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis)
    • Multiple co-morbidities that would make transplantation prohibitively risky
  • Psychosocial parameters
    • Severe mental retardation, psychosis, depression or organic brain syndrome
    • Uncontrolled diabetes mellitus. Once HbA1C < 7, reevaluate for candidacy.
    • Active substance use within 6 months
    • Active smoking within 6 months
    • Active alcoholism within 6 months
    • Inability to comply with transplant-related management and medical follow-up
    • Any other circumstances that deem the candidate high risk from a psychosocial perspective

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

David Lott, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Jaime Engholdt P.A.-C., M.S.

Engholdt.Jaime@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20336411

Mayo Clinic Footer